AK104 + Lenvatinib

Phase 3Recruiting

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Hepatocellular Carcinoma

Conditions

Hepatocellular Carcinoma

Trial Timeline

Aug 2, 2024 → May 23, 2026

NCT ID

NCT06371157

About AK104 + Lenvatinib

AK104 + Lenvatinib is a phase 3 stage product being developed by Akeso for Hepatocellular Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06371157. Target conditions include Hepatocellular Carcinoma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06371157	Phase 3	Recruiting	Aug 2, 2024	May 23, 2026	Hepatocellular Carcinoma
NCT05319431	Phase 2	Active	Jun 28, 2022	Jun 30, 2025	Unresectable, Non-metastatic Hepatocellular Carcinoma
NCT04444167	Phase 1/2	Completed	Jul 7, 2020	Nov 20, 2023	Hepatocellular Carcinoma

Competing Products

20 competing products in Hepatocellular Carcinoma

See all competitors

Product	Company	Stage	Hype Score
CT-01 + EVEROLIMUS	Captor Therapeutics	Phase 1	25
ateganosine + Cadonilimab	MAIA Biotechnology	Phase 1	25
Ramucirumab + Placebo	Eli Lilly	Phase 3	77
ERY974 + Tocilicumab + Atezolizumab + Bevacizumab	Chugai Pharmaceutical	Phase 1	33
Atezolizumab + Bevacizumab + Tiragolumab	Chugai Pharmaceutical	Phase 3	77
GC33(RO5137382) + Sorafenib	Chugai Pharmaceutical	Phase 1	33
CS-1008 2 mg/kg + Sorafenib + CS-1008 6/2 mg/kg + CS-1008 6/6 mg/kg + CS-1008 4 mg/kg + CS-1008 6 mg/kg	Daiichi Sankyo	Phase 2	52
Tivantinib + Placebo	Daiichi Sankyo	Phase 3	77
OSI-906 + Placebo	Astellas Pharma	Phase 2	52
Enzalutamide + Placebo	Astellas Pharma	Phase 2	52
Enzalutamide + Enzalutamide with Sorafenib	Astellas Pharma	Phase 1	33
Recombinant oncolytic virus M1, anti PD-1 antibody, Apatinib	Sun Pharmaceutical	Phase 1	33
Irinotecan + Sonidegib + Sorafenib	Sun Pharmaceutical	Phase 2	52
mFOLFOX7 combined with Camrelizumab and apatinib	Sun Pharmaceutical	Phase 2	52
camrelizumab& apatinib	Sun Pharmaceutical	Phase 2	52
Lenvatinib	Eisai	Pre-clinical	23
Lenvatinib Pill	Eisai	Phase 2	52
Sorafenib + Sorafenib	Eisai	Phase 1/2	41
Lenvatinib	Eisai	Phase 2	52
Lenvatinib + Nivolumab	Eisai	Phase 2	52

Other Products from Akeso

AK104(SC) + AK104(IV) + Capecitabine + Oxaliplatin injectionPhase 3

AK111 + AK111 + PlaceboPhase 3

Cadonilimab (AK104) + Oxaliplatin + Capecitabine + 5- Fluorouracil + Calcium FolinatePhase 3

AK102 + AK102 + Placebo + PlaceboPhase 3

Penpulimab + placeboPhase 3